Single nucleotide polymorphisms and outcome in docetaxel–cisplatin-treated advanced non-small-cell lung cancer
Background: Platinum-based doublets are the standard chemotherapy for advanced non-small-cell lung cancer (NSCLC). Excision-repair cross-complementing 1 (ERCC1), xeroderma pigmentosum group D (XPD) and ribonucleotide reductase subunit M1 (RRM1) are essential to the repair of cisplatin DNA adducts. M...
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2004-08, Vol.15 (8), p.1194-1203 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1203 |
|---|---|
| container_issue | 8 |
| container_start_page | 1194 |
| container_title | Annals of oncology |
| container_volume | 15 |
| creator | Isla, D. Sarries, C. Rosell, R. Alonso, G. Domine, M. Taron, M. Lopez-Vivanco, G. Camps, C. Botia, M. Nuñez, L. Sanchez-Ronco, M. Sanchez, J. J. Lopez-Brea, M. Barneto, I. Paredes, A. Medina, B. Artal, A. Lianes, P. |
| description | Background: Platinum-based doublets are the standard chemotherapy for advanced non-small-cell lung cancer (NSCLC). Excision-repair cross-complementing 1 (ERCC1), xeroderma pigmentosum group D (XPD) and ribonucleotide reductase subunit M1 (RRM1) are essential to the repair of cisplatin DNA adducts. Multidrug resistance 1 (MDR1) has been related to antimicrotubule resistance. We assessed whether single nucleotide polymorphisms (SNPs) in ERCC1, XPD, RRM1 and MDR1, and ERCC1 mRNA expression, predicted survival in docetaxel–cisplatin-treated stage IV NSCLC patients. Patients and methods: Using the TaqMan 5′ nuclease assay, we examined ERCC1 118, XPD 751 and 312, RRM1 −37C/A, and MDR1 C3435T SNPs in peripheral blood lymphocytes (PBLs) obtained from 62 docetaxel–cisplatin-treated advanced NSCLC patients. ERCC1 expression was measured in RNA isolated from PBLs using real-time reverse transcriptase PCR. Results: Overall median survival was 10.26 months. Median survival was 9.67 months for 34 patients with ERCC1 118 C/T, 9.74 months for 17 patients with T/T, and not reached for 11 patients with C/C (P=0.04). Similar significant differences in time to progression were observed according to ERCC1 118 genotype (P=0.03). No other significant differences were observed. Conclusions: Patients homozygous for the ERCC1 118 C allele demonstrated a significantly better survival. ERCC1 SNP assessment could be an important component of tailored chemotherapy trials. |
| doi_str_mv | 10.1093/annonc/mdh319 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66739388</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>66739388</sourcerecordid><originalsourceid>FETCH-LOGICAL-c462t-a74fbbbae207d62f4552820e5d22e118daceaf0119f639d1984dd0bfe69db39f3</originalsourceid><addsrcrecordid>eNpFkM1u1DAUhS0EokNhyRZlAztT_yROvEQVTFsqIfEjITaWY1-3BscOtoPaHe_AG_IkZDQjZnWvdD6de-5B6DklrymR_EzHmKI5m-wtp_IB2tBOSDyQlj5EGyIZx33H2xP0pJTvhBAhmXyMTmjH-p51wwbNn3y8CdDExQRI1Vto5hTup5TnW1-m0uhom7RUkyZofGxsMlD1HYS_v_8YX-agq4-4ZtAVbKPtLx3NuqyZcJl0CNhACE1Y4k1jdlJ-ih45HQo8O8xT9OXd28_nF_j6w_by_M01Nq1gFeu-deM4amCkt4K5tuvYwAh0ljGgdLDagHaEUukEl5bKobWWjA6EtCOXjp-iV3vfOaefC5SqJl92YXSEtBQlRM8lH4YVxHvQ5FRKBqfm7Ced7xUlalex2les9hWv_IuD8TJOYI_0odMVeHkAdDE6uLz-7cuRE4QLKenxsC8V7v7rOv9Qa7a-Uxdfv6nh43smt1dbRfg_EAeZrA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>66739388</pqid></control><display><type>article</type><title>Single nucleotide polymorphisms and outcome in docetaxel–cisplatin-treated advanced non-small-cell lung cancer</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Isla, D. ; Sarries, C. ; Rosell, R. ; Alonso, G. ; Domine, M. ; Taron, M. ; Lopez-Vivanco, G. ; Camps, C. ; Botia, M. ; Nuñez, L. ; Sanchez-Ronco, M. ; Sanchez, J. J. ; Lopez-Brea, M. ; Barneto, I. ; Paredes, A. ; Medina, B. ; Artal, A. ; Lianes, P.</creator><creatorcontrib>Isla, D. ; Sarries, C. ; Rosell, R. ; Alonso, G. ; Domine, M. ; Taron, M. ; Lopez-Vivanco, G. ; Camps, C. ; Botia, M. ; Nuñez, L. ; Sanchez-Ronco, M. ; Sanchez, J. J. ; Lopez-Brea, M. ; Barneto, I. ; Paredes, A. ; Medina, B. ; Artal, A. ; Lianes, P.</creatorcontrib><description>Background: Platinum-based doublets are the standard chemotherapy for advanced non-small-cell lung cancer (NSCLC). Excision-repair cross-complementing 1 (ERCC1), xeroderma pigmentosum group D (XPD) and ribonucleotide reductase subunit M1 (RRM1) are essential to the repair of cisplatin DNA adducts. Multidrug resistance 1 (MDR1) has been related to antimicrotubule resistance. We assessed whether single nucleotide polymorphisms (SNPs) in ERCC1, XPD, RRM1 and MDR1, and ERCC1 mRNA expression, predicted survival in docetaxel–cisplatin-treated stage IV NSCLC patients. Patients and methods: Using the TaqMan 5′ nuclease assay, we examined ERCC1 118, XPD 751 and 312, RRM1 −37C/A, and MDR1 C3435T SNPs in peripheral blood lymphocytes (PBLs) obtained from 62 docetaxel–cisplatin-treated advanced NSCLC patients. ERCC1 expression was measured in RNA isolated from PBLs using real-time reverse transcriptase PCR. Results: Overall median survival was 10.26 months. Median survival was 9.67 months for 34 patients with ERCC1 118 C/T, 9.74 months for 17 patients with T/T, and not reached for 11 patients with C/C (P=0.04). Similar significant differences in time to progression were observed according to ERCC1 118 genotype (P=0.03). No other significant differences were observed. Conclusions: Patients homozygous for the ERCC1 118 C allele demonstrated a significantly better survival. ERCC1 SNP assessment could be an important component of tailored chemotherapy trials.</description><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdh319</identifier><identifier>PMID: 15277258</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Adult ; Aged ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - genetics ; Carcinoma, Non-Small-Cell Lung - pathology ; cisplatin ; Cisplatin - administration & dosage ; DNA Adducts ; DNA Repair ; DNA-Binding Proteins - genetics ; Docetaxel ; Endonucleases - genetics ; ERCC1 ; Female ; Humans ; Lung Neoplasms - drug therapy ; Lung Neoplasms - genetics ; Lung Neoplasms - pathology ; Male ; Medical sciences ; Middle Aged ; non-small-cell lung cancer ; Pharmacology. Drug treatments ; Polymorphism, Single Nucleotide ; Prognosis ; Reverse Transcriptase Polymerase Chain Reaction ; single nucleotide polymorphisms ; Survival Analysis ; Taxoids - administration & dosage ; Treatment Outcome ; Tumors</subject><ispartof>Annals of oncology, 2004-08, Vol.15 (8), p.1194-1203</ispartof><rights>2004 INIST-CNRS</rights><rights>Copyright 2004 European Society for Medical Oncology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c462t-a74fbbbae207d62f4552820e5d22e118daceaf0119f639d1984dd0bfe69db39f3</citedby><cites>FETCH-LOGICAL-c462t-a74fbbbae207d62f4552820e5d22e118daceaf0119f639d1984dd0bfe69db39f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16036991$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15277258$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Isla, D.</creatorcontrib><creatorcontrib>Sarries, C.</creatorcontrib><creatorcontrib>Rosell, R.</creatorcontrib><creatorcontrib>Alonso, G.</creatorcontrib><creatorcontrib>Domine, M.</creatorcontrib><creatorcontrib>Taron, M.</creatorcontrib><creatorcontrib>Lopez-Vivanco, G.</creatorcontrib><creatorcontrib>Camps, C.</creatorcontrib><creatorcontrib>Botia, M.</creatorcontrib><creatorcontrib>Nuñez, L.</creatorcontrib><creatorcontrib>Sanchez-Ronco, M.</creatorcontrib><creatorcontrib>Sanchez, J. J.</creatorcontrib><creatorcontrib>Lopez-Brea, M.</creatorcontrib><creatorcontrib>Barneto, I.</creatorcontrib><creatorcontrib>Paredes, A.</creatorcontrib><creatorcontrib>Medina, B.</creatorcontrib><creatorcontrib>Artal, A.</creatorcontrib><creatorcontrib>Lianes, P.</creatorcontrib><title>Single nucleotide polymorphisms and outcome in docetaxel–cisplatin-treated advanced non-small-cell lung cancer</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><description>Background: Platinum-based doublets are the standard chemotherapy for advanced non-small-cell lung cancer (NSCLC). Excision-repair cross-complementing 1 (ERCC1), xeroderma pigmentosum group D (XPD) and ribonucleotide reductase subunit M1 (RRM1) are essential to the repair of cisplatin DNA adducts. Multidrug resistance 1 (MDR1) has been related to antimicrotubule resistance. We assessed whether single nucleotide polymorphisms (SNPs) in ERCC1, XPD, RRM1 and MDR1, and ERCC1 mRNA expression, predicted survival in docetaxel–cisplatin-treated stage IV NSCLC patients. Patients and methods: Using the TaqMan 5′ nuclease assay, we examined ERCC1 118, XPD 751 and 312, RRM1 −37C/A, and MDR1 C3435T SNPs in peripheral blood lymphocytes (PBLs) obtained from 62 docetaxel–cisplatin-treated advanced NSCLC patients. ERCC1 expression was measured in RNA isolated from PBLs using real-time reverse transcriptase PCR. Results: Overall median survival was 10.26 months. Median survival was 9.67 months for 34 patients with ERCC1 118 C/T, 9.74 months for 17 patients with T/T, and not reached for 11 patients with C/C (P=0.04). Similar significant differences in time to progression were observed according to ERCC1 118 genotype (P=0.03). No other significant differences were observed. Conclusions: Patients homozygous for the ERCC1 118 C allele demonstrated a significantly better survival. ERCC1 SNP assessment could be an important component of tailored chemotherapy trials.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - genetics</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>cisplatin</subject><subject>Cisplatin - administration & dosage</subject><subject>DNA Adducts</subject><subject>DNA Repair</subject><subject>DNA-Binding Proteins - genetics</subject><subject>Docetaxel</subject><subject>Endonucleases - genetics</subject><subject>ERCC1</subject><subject>Female</subject><subject>Humans</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - genetics</subject><subject>Lung Neoplasms - pathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>non-small-cell lung cancer</subject><subject>Pharmacology. Drug treatments</subject><subject>Polymorphism, Single Nucleotide</subject><subject>Prognosis</subject><subject>Reverse Transcriptase Polymerase Chain Reaction</subject><subject>single nucleotide polymorphisms</subject><subject>Survival Analysis</subject><subject>Taxoids - administration & dosage</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkM1u1DAUhS0EokNhyRZlAztT_yROvEQVTFsqIfEjITaWY1-3BscOtoPaHe_AG_IkZDQjZnWvdD6de-5B6DklrymR_EzHmKI5m-wtp_IB2tBOSDyQlj5EGyIZx33H2xP0pJTvhBAhmXyMTmjH-p51wwbNn3y8CdDExQRI1Vto5hTup5TnW1-m0uhom7RUkyZofGxsMlD1HYS_v_8YX-agq4-4ZtAVbKPtLx3NuqyZcJl0CNhACE1Y4k1jdlJ-ih45HQo8O8xT9OXd28_nF_j6w_by_M01Nq1gFeu-deM4amCkt4K5tuvYwAh0ljGgdLDagHaEUukEl5bKobWWjA6EtCOXjp-iV3vfOaefC5SqJl92YXSEtBQlRM8lH4YVxHvQ5FRKBqfm7Ced7xUlalex2les9hWv_IuD8TJOYI_0odMVeHkAdDE6uLz-7cuRE4QLKenxsC8V7v7rOv9Qa7a-Uxdfv6nh43smt1dbRfg_EAeZrA</recordid><startdate>20040801</startdate><enddate>20040801</enddate><creator>Isla, D.</creator><creator>Sarries, C.</creator><creator>Rosell, R.</creator><creator>Alonso, G.</creator><creator>Domine, M.</creator><creator>Taron, M.</creator><creator>Lopez-Vivanco, G.</creator><creator>Camps, C.</creator><creator>Botia, M.</creator><creator>Nuñez, L.</creator><creator>Sanchez-Ronco, M.</creator><creator>Sanchez, J. J.</creator><creator>Lopez-Brea, M.</creator><creator>Barneto, I.</creator><creator>Paredes, A.</creator><creator>Medina, B.</creator><creator>Artal, A.</creator><creator>Lianes, P.</creator><general>Oxford University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20040801</creationdate><title>Single nucleotide polymorphisms and outcome in docetaxel–cisplatin-treated advanced non-small-cell lung cancer</title><author>Isla, D. ; Sarries, C. ; Rosell, R. ; Alonso, G. ; Domine, M. ; Taron, M. ; Lopez-Vivanco, G. ; Camps, C. ; Botia, M. ; Nuñez, L. ; Sanchez-Ronco, M. ; Sanchez, J. J. ; Lopez-Brea, M. ; Barneto, I. ; Paredes, A. ; Medina, B. ; Artal, A. ; Lianes, P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c462t-a74fbbbae207d62f4552820e5d22e118daceaf0119f639d1984dd0bfe69db39f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - genetics</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>cisplatin</topic><topic>Cisplatin - administration & dosage</topic><topic>DNA Adducts</topic><topic>DNA Repair</topic><topic>DNA-Binding Proteins - genetics</topic><topic>Docetaxel</topic><topic>Endonucleases - genetics</topic><topic>ERCC1</topic><topic>Female</topic><topic>Humans</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - genetics</topic><topic>Lung Neoplasms - pathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>non-small-cell lung cancer</topic><topic>Pharmacology. Drug treatments</topic><topic>Polymorphism, Single Nucleotide</topic><topic>Prognosis</topic><topic>Reverse Transcriptase Polymerase Chain Reaction</topic><topic>single nucleotide polymorphisms</topic><topic>Survival Analysis</topic><topic>Taxoids - administration & dosage</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Isla, D.</creatorcontrib><creatorcontrib>Sarries, C.</creatorcontrib><creatorcontrib>Rosell, R.</creatorcontrib><creatorcontrib>Alonso, G.</creatorcontrib><creatorcontrib>Domine, M.</creatorcontrib><creatorcontrib>Taron, M.</creatorcontrib><creatorcontrib>Lopez-Vivanco, G.</creatorcontrib><creatorcontrib>Camps, C.</creatorcontrib><creatorcontrib>Botia, M.</creatorcontrib><creatorcontrib>Nuñez, L.</creatorcontrib><creatorcontrib>Sanchez-Ronco, M.</creatorcontrib><creatorcontrib>Sanchez, J. J.</creatorcontrib><creatorcontrib>Lopez-Brea, M.</creatorcontrib><creatorcontrib>Barneto, I.</creatorcontrib><creatorcontrib>Paredes, A.</creatorcontrib><creatorcontrib>Medina, B.</creatorcontrib><creatorcontrib>Artal, A.</creatorcontrib><creatorcontrib>Lianes, P.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Isla, D.</au><au>Sarries, C.</au><au>Rosell, R.</au><au>Alonso, G.</au><au>Domine, M.</au><au>Taron, M.</au><au>Lopez-Vivanco, G.</au><au>Camps, C.</au><au>Botia, M.</au><au>Nuñez, L.</au><au>Sanchez-Ronco, M.</au><au>Sanchez, J. J.</au><au>Lopez-Brea, M.</au><au>Barneto, I.</au><au>Paredes, A.</au><au>Medina, B.</au><au>Artal, A.</au><au>Lianes, P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Single nucleotide polymorphisms and outcome in docetaxel–cisplatin-treated advanced non-small-cell lung cancer</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2004-08-01</date><risdate>2004</risdate><volume>15</volume><issue>8</issue><spage>1194</spage><epage>1203</epage><pages>1194-1203</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><abstract>Background: Platinum-based doublets are the standard chemotherapy for advanced non-small-cell lung cancer (NSCLC). Excision-repair cross-complementing 1 (ERCC1), xeroderma pigmentosum group D (XPD) and ribonucleotide reductase subunit M1 (RRM1) are essential to the repair of cisplatin DNA adducts. Multidrug resistance 1 (MDR1) has been related to antimicrotubule resistance. We assessed whether single nucleotide polymorphisms (SNPs) in ERCC1, XPD, RRM1 and MDR1, and ERCC1 mRNA expression, predicted survival in docetaxel–cisplatin-treated stage IV NSCLC patients. Patients and methods: Using the TaqMan 5′ nuclease assay, we examined ERCC1 118, XPD 751 and 312, RRM1 −37C/A, and MDR1 C3435T SNPs in peripheral blood lymphocytes (PBLs) obtained from 62 docetaxel–cisplatin-treated advanced NSCLC patients. ERCC1 expression was measured in RNA isolated from PBLs using real-time reverse transcriptase PCR. Results: Overall median survival was 10.26 months. Median survival was 9.67 months for 34 patients with ERCC1 118 C/T, 9.74 months for 17 patients with T/T, and not reached for 11 patients with C/C (P=0.04). Similar significant differences in time to progression were observed according to ERCC1 118 genotype (P=0.03). No other significant differences were observed. Conclusions: Patients homozygous for the ERCC1 118 C allele demonstrated a significantly better survival. ERCC1 SNP assessment could be an important component of tailored chemotherapy trials.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>15277258</pmid><doi>10.1093/annonc/mdh319</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2004-08, Vol.15 (8), p.1194-1203 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_66739388 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adult Aged Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - pathology cisplatin Cisplatin - administration & dosage DNA Adducts DNA Repair DNA-Binding Proteins - genetics Docetaxel Endonucleases - genetics ERCC1 Female Humans Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - pathology Male Medical sciences Middle Aged non-small-cell lung cancer Pharmacology. Drug treatments Polymorphism, Single Nucleotide Prognosis Reverse Transcriptase Polymerase Chain Reaction single nucleotide polymorphisms Survival Analysis Taxoids - administration & dosage Treatment Outcome Tumors |
| title | Single nucleotide polymorphisms and outcome in docetaxel–cisplatin-treated advanced non-small-cell lung cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T09%3A54%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Single%20nucleotide%20polymorphisms%20and%20outcome%20in%20docetaxel%E2%80%93cisplatin-treated%20advanced%20non-small-cell%20lung%20cancer&rft.jtitle=Annals%20of%20oncology&rft.au=Isla,%20D.&rft.date=2004-08-01&rft.volume=15&rft.issue=8&rft.spage=1194&rft.epage=1203&rft.pages=1194-1203&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdh319&rft_dat=%3Cproquest_cross%3E66739388%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=66739388&rft_id=info:pmid/15277258&rfr_iscdi=true |